Fig. 1: Suggested management of the axilla with T1/T2 N1 disease who are triple negative or HER2 amplified. | npj Breast Cancer

Fig. 1: Suggested management of the axilla with T1/T2 N1 disease who are triple negative or HER2 amplified.

From: Management of the axilla in T1-2N1 breast cancer

Fig. 1

(Patients who are cN0 after neoadjuvant chemotherapy and have a positive sentinel node may be candidates for the Alliance A011202 trial, which randomized patients to a full axillary lymph node dissection versus none; all patients will receive radiation therapy). TNBC triple-negative breast cancer, HER2 human epidermal growth factor receptor 2, CTx chemotherapy, SLNB sentinel lymph node biopsy, XRT radiation therapy, ALND axillary lymph node dissection.

Back to article page